Bicara Therapeutics grants 285,000 options to CFO

Q: What is the exercise price of the new stock options granted to the BCAX CFO?

The stock options granted to the BCAX CFO have an exercise price of $24.63 per share. This is the price at which she can purchase common stock upon exercise, once the options have vested and before they expire on August 12, 2036.

Q: How do the 285,000 BCAX stock options granted to the CFO vest over time?

The 285,000 BCAX stock options vest as follows: 25% vest on August 12, 2027, and the remaining 75% vest in twelve equal quarterly installments thereafter, contingent on Jennifer Larson’s continued service on each vesting date.

Q: When do the newly granted BCAX stock options to the CFO expire?

The newly granted BCAX stock options to the CFO expire on August 12, 2036. She may exercise vested options at the $24.63 exercise price any time after vesting and before this expiration date, subject to plan terms.

Q: How many BCAX derivative securities does the CFO hold after this stock option grant?

After this grant, the CFO holds 285,000 derivative securities of this stock option type directly. Each option represents the right to acquire one share of Bicara Therapeutics common stock, subject to the specified vesting schedule and expiration date.

Bicara Therapeutics Inc. reported that its Chief Financial Officer, Jennifer Larson, received a grant of 285,000 stock options on August 12, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reported that its Chief Financial Officer, Jennifer Larson, received a grant of 285,000 stock options on August 12, 2026. The options have an exercise price of $24.63 per share and are exercisable for an equal number of shares of common stock until August 12, 2036. According to the vesting terms, 25% of the options vest and become exercisable on August 12, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to her continued service. Following this award, she holds 285,000 derivative securities of this type directly.

Insider Trade Summary

Grant/Award: 285,000 shares

Grant/Award 1 txn

Insider Larson Jennifer

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	285,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 285,000 contracts (Direct)

Footnotes (1)

F1. 25% of the shares subject to this option vest and become exercisable on August 12, 2027, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock options granted: 285,000 options Exercise price: $24.63 per share Expiration date: August 12, 2036 +3 more

6 metrics

Stock options granted 285,000 options Grant of stock options to CFO on August 12, 2026

Exercise price $24.63 per share Exercise price of the CFO’s stock option grant

Expiration date August 12, 2036 Expiration of the granted stock options

Initial vesting tranche 25% on August 12, 2027 First vesting date and portion of options

Remaining vesting schedule 12 equal quarterly installments Remainder of options vesting after August 12, 2027

Post-grant holdings 285,000 derivative securities Total stock options of this type held directly after grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, quarterly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 24.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to this option vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

quarterly installments financial

"remainder vesting in twelve equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bicara Therapeutics (BCAX) disclose about Jennifer Larson’s recent equity award?

Bicara Therapeutics disclosed that CFO Jennifer Larson received a grant of 285,000 stock options on August 12, 2026, giving her the right to buy an equal number of common shares at $24.63 per share, subject to vesting and expiration terms.

What is the exercise price of the new stock options granted to the BCAX CFO?

The stock options granted to the BCAX CFO have an exercise price of $24.63 per share. This is the price at which she can purchase common stock upon exercise, once the options have vested and before they expire on August 12, 2036.

How do the 285,000 BCAX stock options granted to the CFO vest over time?

The 285,000 BCAX stock options vest as follows: 25% vest on August 12, 2027, and the remaining 75% vest in twelve equal quarterly installments thereafter, contingent on Jennifer Larson’s continued service on each vesting date.

When do the newly granted BCAX stock options to the CFO expire?

The newly granted BCAX stock options to the CFO expire on August 12, 2036. She may exercise vested options at the $24.63 exercise price any time after vesting and before this expiration date, subject to plan terms.

How many BCAX derivative securities does the CFO hold after this stock option grant?

After this grant, the CFO holds 285,000 derivative securities of this stock option type directly. Each option represents the right to acquire one share of Bicara Therapeutics common stock, subject to the specified vesting schedule and expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/14/2026 - 04:54 PM Accepted by SEC EDGAR 08/14/2026 - 04:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Larson Jennifer

(Last)

(First)

(Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON

MASSACHUSETTS

02116

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$24.63	08/12/2026		A		285,000		⁽¹⁾	08/12/2036	Common Stock	285,000	$0	285,000	D

Explanation of Responses:

1. 25% of the shares subject to this option vest and become exercisable on August 12, 2027, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Ryan Cohlhepp, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR